Insider filing · ASMB

Gilead Sciences, Inc. bought $55.0M of Assembly Biosciences (ASMB)

Executed Aug 8 2025, disclosed Oct 3 2025, 56 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Oct 3 2025), the stock returned +30.6% (delay-adjusted); from the execution session (Aug 8 2025), +7.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

GI Gilead Sciences, Inc. 10% owner profile →

Gilead Sciences, Inc. (10% owner) filed 4 Form 4 reports as a reporting entity in the past 24 months (4 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Assembly Biosciences, Inc. (ASMB). Across 4 priced purchase filings, the average 21-session return was +4.2% from execution and +0.5% from disclosure (delay-adjusted; derived). The largest single filing was $55.0M of ASMB (as filed), executed Aug 8 2025.

ASMB Assembly Biosciences, Inc. ASMB · Healthcare · 4 filings in 24 months ticker →

Healthcare · Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→